Global Glaucoma Medications Market Size, Share & Trends Analysis Report, By Indication (Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, and Others), By Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, and Others), Forecast (2022-2028)

The global glaucoma medications market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Glaucoma is the eye disease that damages the optic nerve and causes vision loss. It mostly occurs in people over the age of 40, however, congenital glaucoma is also observed across the globe. The growing geriatric population is one of the key factors that results in the rising incidences of glaucoma disease globally. The incidence and prevalence rate of glaucoma disease is growing at a significant rate across the globe. According to the World Health Organization (WHO), in 2019, around 2.2 billion people from across the globe had been suffering from one or the other kind of visual impairment and 80% of these were considered avoidable. In the US, glaucoma is the second leading cause of blindness after cataracts. This significant prevalence of the disease creates the demand for glaucoma medications, thereby spurring its market growth.
Some key players operating in the market include Bausch & Lomb Inc., Novartis International AG, and Mylan NV, among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in September 2020, Micro Labs USA Inc. announces its presence in the US Ophthalmic market by launching two products, such as Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL. Dorzolamide and Dorzolamide-Timolol are widely used for treating Glaucoma, a condition characterized by increased intra-ocular pressure.

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered- 
By Indication
By Drug Class

Regions covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape:
Bausch & Lomb Inc., Novartis International AG, and Mylan NV, among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How are players addressing challenges to sustain growth?
Where is the investment opportunity?

Global Glaucoma Medications Market Report by Segment
By Indication
Open Angle Glaucoma
Closed Angle Glaucoma
Secondary Glaucoma
Congenital Glaucoma
Others

By Drug Class
Prostaglandin Analogs
Beta Blockers
Alpha-Agonist
Carbonic Anhydrase Inhibitors
Others